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Summary
We estimated the rates per base per generation of specific
types of mutations, using our direct estimate of the over-
all mutation rate for hemophilia B and information on
the mutations present in the United Kingdom’s popu-
lation as well as those reported year by year in the he-
mophilia B world database. These rates are as follows:
transitions at CpG sites , other transitions589.7# 10
, transversions at CpG sites ,59 597.3# 10 5.4# 10
other transversions , and small deletions/in-596.9# 10
sertions causing frameshifts . By taking into5103.2# 10
account the ratio of male to female mutation rates, the
above figures were converted into rates appropriate for
autosomal DNA—namely, , ,57 591.3# 10 9.9# 10
, , , where the latter59 59 5107.3# 10 9.4# 10 6.5# 10
is the rate for all small deletion/insertion events. Mu-
tation rates were also independently estimated from the
sequence divergence observed in randomly chosen se-
quences from the human and chimpanzee X and Y chro-
mosomes. These estimates were highly compatible with
those obtained from hemophilia B and showed higher
mutation rates in the male, but they showed no evidence
for a significant excess of transitions at CpG sites in the
spectrum of Y-sequence divergence relative to that of X-
chromosome divergence. Our data suggest an overall
mutation rate of per base per generation,-82.14# 10
or 128 mutations per human zygote. Since the effective
target for hemophilia B mutations is only 1.05% of the
factor IX gene, the rate of detrimental mutations, per
human zygote, suggested by the hemophilia data is ∼1.3.
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Introduction
Data on spontaneous human mutation rates are still
scarce. Locus mutation rates based on dominantly in-
herited diseases have been obtained (Vogel and Motulsky
1997), but dominant diseases present several difficulties.
They often show incomplete, unpredictable penetrance.
Some dominant diseases—for example, Huntington
disease (MIM 14310)—arise by a distinct mutational
mechanism: triplet expansion (The Huntington’s Disease
Collaborative Group 1993). Furthermore, in general,
dominant mutations causing gain of function or domi-
nant negative effects are likely to show narrow spectra
and rather restricted intragenic targets. Mutation rates
more representative of the changes responsible for the
evolution of the bulk of the genome can be obtained
from X-linked recessive diseases, which are particularly
convenient because the natural X monosomy of the male
allows detection of any recessive mutation. However,
extrapolation from mutation rates in X-linked genes to
those in the whole genome requires determination of the
ratio of sex-specific mutation rates. Among the X-linked
recessive diseases the hemophilias are ideal, because they
are caused by mutations that do not result in balanced
polymorphisms, and the mutation-selection equilibrium
that has existed until recently ensures a substantial pro-
portion of recent mutations in the hemophilia popula-
tions (Tuddenham and Giannelli 1994). Furthermore, as
mentioned in the accompanying paper (Green et al. 1999
[in this issue]), full ascertainment of hemophilia patients
is closely approached in countries where national patient
registers have been established. Of the two hemophilias
(MIM 30670 and MIM 30690), hemophilia B (MIM
30690) is the most useful at present, because the stan-
dard size of the factor IX gene allowed the development
of satisfactory mutation-detection procedures 10 years
ago, and this has led to the collection of abundant in-
formation on hemophilia B mutations. A world database
of such mutations was assembled in 1990 and is updated
annually (Giannelli et al. 1990, 1998).
We have conducted a national study of the United
Kingdom’s hemophilia B population that has allowed
direct estimates of the overall and sex-specific mutation
rates (Green et al. 1999). Here, we use the results of this
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Table 1
Estimation of Hemophilia B Point Mutation Target Size in the Factor IX Coding Sequence
POINT MUTATION TYPE
NO. OF
POSSIBLE
CHANGESa
NO. OF DISEASE-CAUSING CHANGES FOUND
TARGET
SIZEc
Up to
1997 (x)
In 1998 and 1999
Estimated Changes
Not Seen up
to 1997b (q)
Previously
Observed (y)
Not Previously
Observed (z)
Transitions:
CpG 31 20 18 0 0 20
Non-CpG 892 185 50 26 96.2 281.2
Transversions [CpG transversions] 2,352 [65] 208 [19] 29 [1] 44 [1] 315.6 [19] 523.6 [38]
Total 3,275 413 97 70 411.8 824.8
a Nonsynonymous base substitutions only. The total number of base substitutions is 4,086, of which 120 are at CpG sites.
b Derived by use of the formula q = xz/y, where each letter corresponds to the appropriate value for each type of mutation in
columns x, y, z, and q. Data in column x are from Giannelli et al. (1997), and those in columns y and z are from Giannelli et al.
(1998) and Burks et al. (1999).
c Derived from x  q: it indicates the number of base substitutions expected to cause hemophilia B. Note that, since each base
can undergo three different substitutions, a total target of 825 is equivalent to 275 bases.
study, plus information from the world database of he-
mophilia B mutations, to estimate the rates of different
base substitutions and small deletions/insertions. In ad-
dition, we estimate mutation rates from interspecies se-
quence divergences, between humans and chimpanzees,
that were observed in both X and Y chromosome se-
quences. These rates are compared with those obtained
from hemophilia B. Finally, using the data on hemophilia
B, we attempt to estimate the rate of detrimental mu-
tations per human zygote.
Material and Methods
Identification of Hemophilia B Mutations and
Determination of their Independent Origin
The methods used to characterize hemophilia B mu-
tations and the criteria to determine their independent
origin have been described in the accompanying paper
(Green et al. 1999 [in this issue]).
Sequencing of Chimpanzee DNA and of a Reference
Human DNA
Using the human genomic sequence available in the
public databases, we have designed 42 PCR reactions of
∼1.5 kb each in an Xq22 region spanning ∼5 Mb (for
details, see Anagnostopoulos et al. [1999]). These were
arranged in seven clusters representing cosmid inserts.
Each cosmid sequence contained six PCR reactions
placed an average of 5 kb apart. Eleven similar but over-
lapping reactions were designed from unique Y-chro-
mosome sequence (Whitfield et al. 1995). Twenty two
X-chromosome and six Y-chromosome reactions were
successful on both human and chimpanzee DNAs. The
ends of the PCR products obtained by the above reaction
in the chimpanzee’s and a human male’s DNA were
sequenced with the PCR primers used in dRhodamineTM
dye terminator cycle sequencing, according to the man-
ufacturer’s protocol (PE Biosystems).
Results
Type-Specific Mutation Rates
In the accompanying paper (Green et al. 1999 [in this
issue]), we have obtained the overall and sex-specific
rates for hemophilia B mutations, and have observed
that the sex ratio for different types of mutations does
not differ significantly. To determine the rates of specific
types of mutations from the hemophilia B data, it is
necessary to know the effective target size for the dif-
ferent hemophilia B mutations. This can be fairly ac-
curately determined for hemophilia B mutations that are
caused by base substitutions resulting in nonsense or
missense mutations.
Since the coding sequence of the FIX gene specifies 39
amino acids of prepropeptide and 415 amino acids of
circulating FIX protein, it contains 1,362 bp and can
experience 4,086 different base substitutions. Of these,
811 are synonymous and 24 occur at CpG sites. The
remaining 3,275 result in nonsense or missense muta-
tions (table 1). The latter subdivide as follows: 31 tran-
sitions at CpG sites; 892 other transitions; and 2,352
transversions, of which 65 are at CpG sites. Not all these
mutations can be expected to result in hemophilia B,
and, to determine the fraction of disease-causing mu-
tations, we use the following rationale. The 1997 world
database of hemophilia B mutations, with 1,552 entries
(Giannelli et al. 1997), gives the fullest list up to 1997
of different base substitutions causing hemophilia B
mutations. Within the factor IX coding sequence this
amounts to 20 transitions at CpGs, 185 other transi-
tions, and 208 transversions, of which 19 are at CpG
sites. The number of mutations of these types that re-
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Table 2
Estimate of Type-Specific Mutation Rates based on Factor IX
Coding Sequences
Mutation Type
Target
Size (x)a
No. of
Independent
Mutations (y)b
Estimated
Mutation
Ratec
(# 1010)
Transitions:
CpG 20 76 m1 = 973
Non-CpG 281.2 80 m2 = 72.8
Transversions:
All 523.6 70 m3 = 68.4
Non-CpG 485.6 66 mu = 69.6
CpG 38 4 mv = 53.9
All base substitutions 824.8 226 m4 = 210
Small deletions/insertions
causing frameshifts 1,362 17 m5 = 3.19
All above types m6 = 213
a No. of different base substitutions expected to cause hemophilia
B or of positions where frameshift mutations may occur through small
deletions/insertions.
b Observed in the factor IX coding sequence of hemophilia B pa-
tients from the United Kingdom.
c The formula used for estimation is (see text). m =nmy /tx = mi i i i
7.733 # 106; t = 302; i = 1, 2, 3, 4, 5, 6, u, or v. Note that ismi
expressed per base per generation and that m and t have been deter-
mined in the accompanying article (Green et al. 1999 [in this issue]).
mained undetected up to 1997 is obviously proportional
to the fraction of different mutations enlisted in the fol-
lowing 2 years (Giannelli et al. 1998; Burks 1999) that
had not been observed previously. Thus, the estimate of
the number of different mutations that remained un-
detected up to 1997 is given, for each class, by q =
, where x is the number of different mutations inxz/y
the 1997 database, y the number of different mutations
reported to the database by 1998 and 1999 that had
been seen previously, and z the number of mutations
novel in these last 2 years of referrals (table 1). This
approach could overestimate the target for hemophilia
B mutations and thus could result in an underestimation
of mutation rates per nucleotide if the submissions to
the hemophilia B database in 1998 and 1999 were biased
in favor of mutations that had not been previously ob-
served. The likelihood of this event is small, because
contributions to the database are always made year after
year by the same set of national coordinators, who pro-
vide largely unpublished information on the precise un-
derstanding that all well-characterized mutations are
equally valuable irrespective of whether they have been
observed previously. The sum of q and x for the above
groups of mutations indicates that the number of dif-
ferent missense or nonsense mutations that can cause
hemophilia B should consist of 20 transitions at CpG
sites, 281.2 transitions at other sites, and 523.6 trans-
versions, of which 38 are at CpG sites, thus defining, in
the coding sequence of the factor IX gene, a total target
of 824.8 different point mutations severe enough to
cause hemophilia B. This is a target equivalent to 275
nucleotides. The target size for small deletion/insertion
mutations can also be determined. A convenient ap-
proximation is to consider the creation of a frameshift
as the means by which these mutations cause hemophilia
B. In a coding region of 1,362 nucleotides, there are as
many positions at which frameshifts may occur, and
these may be caused by deletions or insertions of one or
two bases or multiples thereof. Therefore, frameshifts
can occur at 1,362 positions because of a variety of
mutations involving deletions, insertions, or both dele-
tions and insertions.
If we now consider both the proportion of indepen-
dent mutations of the above different types that were
observed in the United Kingdom and the estimate of the
overall mutation rate obtained from the same popula-
tion, we can calculate the type-specific mutation rates
per nucleotide per generation (table 2), using the formula
where is 1 for transitions and small deletions/n my /tx ni i i i
insertions, 2 for transversions, and 3 for all base sub-
stitutions, m is the overall mutation rate, the numberyi
of independent mutations of a specific type found in the
United Kingdom in the factor IX coding sequence, t the
total number of independent mutations observed in the
United Kingdom, and the number of events definingxi
the target for each specific type of mutation. This for-
mula partitions m into its components by attributing to
each mutation type a rate value proportional to its oc-
currence in the U.K. population ( ). In addition, thesey /ti
rates are related to the hemophilia B effective target in
nucleotide equivalents for each type of mutation ( ).n /xi i
Thus, the mutation type–specific rates are expressed per
nucleotide per generation, rather than per gene per gen-
eration as done for m. The rates estimated are as follows:
transitions at CpG sites, ; other transitions,89.73 # 10
; transversions, ; all base sub-9 97.28 # 10 6.84 # 10
stitutions, ; frameshifts, and8 102.10 # 10 3.19 # 10
all mutations combined, .82.13 # 10
From Hemophilia B to the Bulk of the Genome
To apply the above rates to the genome as a whole,
one has to consider three additional facts. Since the X
chromosome—and, hence, the factor IX gene—spends
one-third of its life in the male, whereas the autosomes
spend equal times in both sexes, it follows that X-linked
genes will show a lower rate of mutation than the au-
tosomes whenever the mutation rates are higher in the
male.
For a ratio of male to female mutation rate v/u =
the autosome–to–X-chromosome mutation-rate8.64
ratio is . In[3 # (8.64 1)]/[2 # (8.64 2)] = 1.359
addition, the rate of frameshifts in the coding region of
the factor IX gene must be multiplied by 1.5, to account
for the small deletions/insertions of 3 bp or multiples
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Table 3
Estimates of Type-Specific Mutation Rates for X and Y Chromosome Sequences, Based on Chimpanzee-to-Human Sequence
Divergence
MUTATION TYPE
X CHROMOSOME Y CHROMOSOME
Target Size
(bp)
No. of Mutations
Observed
Estimated Ratea
(# 1010)
Target Size
(bp)
No. of Mutations
Observed
Estimated Ratea
(# 1010)
Transitions:
CpG 194 10 m1 = 51.5 78 9 v1 = 115
Non-CpG 13,766 54 m2 = 3.92 4,592 32 v2 = 7.00
Transversions 13,960 33 m3 = 2.36 4,670 16 v3 = 3.44
All base substitutions 13,960 97 m4 = 6.94 4,670 57 v4 = 12.2
Small deletions/insertions 13,960 4 m5 = 0.286 4,670 6 v5 = 1.29
All mutations 13,960 101 m6 = 7.23 4,670 63 v6 = 13.5
a Mutation rates and are expressed per base per year; m4 and v4 are obtained by addition of m3 and v3, respectively, to the weightedm vi i
average of m1 and m2 or v1 and v2; the time when species diverged is taken to be 5 million years ago. The above data are from
Anagnostopoulos et al. (1999).
thereof that do not cause frameshifts and that, because
of their unpredictable phenotypic effect, were not con-
sidered in the context of hemophilia B. Of course, this
assumes that deletions/insertions of 3 bp or multiples
thereof are as likely to occur as those of 1 or 2 bp and
their respective multiples (that cause frameshifts). In this
way, an estimate for the rate of small deletions/insertions
is obtained. Finally, one has to correct for the excessive
representation of CpG sites, since we have previously
noted evidence suggesting a fourfold enrichment of CpG
sites in critical positions of the factor IX gene (Green et
al. 1992). The present data offer the following evidence
of CpG enrichment in the critical target for hemophilia
B. The proportion of CpG-site substitutions capable of
causing hemophilia B (58:96—see first columns of tables
1 and 2) is 2.5-fold greater than that at other sites in
the factor IX coding sequence (766.8:3,179). Further-
more, the CpG-site substitutions that are expected to be
able to cause hemophilia B represent 7% of the hemo-
philia B effective target (58:824.8), whereas the fre-
quency of nucleotides forming CpG sites in our ran-
domly chosen X-chromosome sequences (table 3) was
1.4% (194:13,690)—that is, five times lower. The ran-
domly chosen X-chromosome sequences should be more
representative of the human genome, because the coding
sequence of the factor IX gene is exposed to strong se-
lection against detrimental mutations. After the fivefold
overrepresentation of CpG sites in the target site for
hemophilia B mutations is corrected for and the other
adjustments mentioned above are made, the following
values are obtained for the autosomal rates of mutation
per base per generation: transitions at CpG71.32 # 10
sites, transitions at non-CpG sites,99.88 # 10
transversions, base substitu-9 89.28 # 10 2.08 # 10
tions, small deletions/insertions, and106.49 # 10
small mutations combined, where the latter82.14 # 10
is an average weighted by target size.
Comparison of Mutation Rates Derived from
Hemophilia B and Interspecies Sequence Divergence
Data
Recently we have compared X- and Y-chromosome
sequences from a man and a male chimpanzee (Anag-
nostopoulos et al. [1999]). The sequences comprised
13,960 bp from the X and 4,670 bp from the Y chro-
mosome (table 3), representing short stretches of DNA
at many randomly selected sites. The X-chromosome
sequences showed 64 transitions (including 10 at CpG
sites), 33 transversions and 4 small deletion/insertions,
and the Y chromosome showed 41 transitions (including
9 at CpG sites), 16 transversions, and 6 small deletion/
insertion mutations. It is worth noting that the ratio of
transitions at CpG to those not at CpG sites is similar
for the X- and Y-chromosome sequences. Logistic re-
gression clearly showed that, whereas there are signifi-
cant differences between transitions at and transitions
not at CpG sites ( ) and between transitions onP ! .0001
the X and Y chromosomes ( ), there is no sig-P = .0014
nificant effect of chromosome on the ratio of transitions
occurring at CpG to those at other sites, as tested by the
interaction between chromosomes and CpG/non-CpG
sites ( ). This negates a particular and marked ex-P = .56
cess of CpG transitions in the male, relative to the fe-
male, germline.
From the sequence-divergence data, the following
rates of mutations per base per year can be obtained for
the X chromosome (table 3), if it is assumed that there
has been 5 million years of separation between the two
species (White et al. 1994) and, hence, a combined 10
million years of mutation accumulation during diver-
gence: transitions at CpG sites,95.15 # 10 3.92 #
transitions at non-CpG sites, trans-10 1010 2.36 # 10
versions, base substitutions,106.94 # 10 2.86 #
small deletions/insertions, and for11 1010 7.23 # 10
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small deletions/insertions and base substitutions com-
bined. Similarly, data on the Y chromosome (table 3)
gave the following rates per nucleotide per year:
transitions at CpG sites, tran-9 1011.5 # 10 7.00 # 10
sitions at non-CpG sites, transversions,103.44 # 10
base substitutions, deletions/9 101.22 # 10 1.29 # 10
insertions, and for small deletions/inser-91.35 # 10
tions and base substitutions combined. Furthermore,
comparison of the sequence-divergence rates in the X
and Y sequences suggests an average ratio of male to
female mutation rates of 3.5 over the 10 million years
of separate evolution. When this factor is taken into
account, the rate of mutations for the autosomes or the
bulk of the genome over the period of species divergence
becomes CpG transitions,9 106.32 # 10 4.81 # 10
non-CpG transitions, transversions,102.89 # 10
base substitutions, small de-10 118.51 # 10 3.51 # 10
letion/insertions, and all small mutation108.87 # 10
types combined per nucleotide per year. As mentioned
earlier, the frequency of CpG sites in the above X-chro-
mosome sequences is fivefold lower than that observed
in the effective hemophilia B target. The above rates
calculated from divergence data and those obtained from
hemophilia B are in good agreement, particularly if one
considers the uncertainties about the precise period of
divergence and the most appropriate generation times
for the two species over this time. When the type-specific
mutation rates per base per generation that are calcu-
lated from the hemophilia B data are divided by the
mutation rate per base per year calculated from the di-
vergence of human and chimpanzee sequences, values
are obtained that are compatible with the length of hu-
man generations (table 4).
Estimate of the Spontaneous Rate of Detrimental
Mutations in Humans
Data on the rates of spontaneous mutations recently
have been reviewed, and the question of whether the
high spontaneous rate is a health risk has been raised
(Crow 1997; Drake et al. 1998). These reviews under-
score the difficulties presented by our species for esti-
mation of the genomic rate of detrimental mutations, as
well as the need for additional human data. We have
used our study of hemophilia B in the United Kingdom
to provide information on spontaneous-mutation rates.
The use of a disease phenotype is particularly apt for
consideration of the distinction between the general
spontaneous rate of mutation and that of detrimental
mutations, where “detrimental” is defined as a clinically
detectable effect in the hemizygous male such that ge-
netic fitness is likely to be decreased. Our data indicate
that a human zygote with a genome of bp96 # 10
should contain 128.4 mutations. However, only a small
fraction of these mutations may be detrimental. This
fraction can be roughly estimated by consideration of
the nucleotide equivalent of the effective target for he-
mophilia B mutations and the nucleotide content of the
factor IX gene. Since 824.8 different base substitutions
in the factor IX coding sequence are expected to cause
hemophilia B, and 3 substitutions may occur at any nu-
cleotide, this effective target is equivalent to 275 nucle-
otides. Small deletions and insertions causing hemophilia
B by frameshift mutation may occur at 1,362 nucleo-
tides, but such mutations occur at a rate ∼66-fold lower
than that of base substitutions, and, therefore, the ef-
fective target for hemophilia B mutations affecting the
coding region is nucleotides.[275 (1,362/66)] = 295.6
Some hemophilia B mutations occur in the noncoding
region of factor IX or are in-frame deletions/insertions
or gross deletions. In the United Kingdom, these mu-
tations represent 19.5%, of the total. Thus, the effective
target for hemophilia B can be further increased by
19.5% to 353.2 nucleotides. Since the factor IX is
33,500 nucleotides long, only 1.05% of mutations oc-
curring in the gene can be expected to cause hemophilia
B. If one applies this figure to the whole genome, only
1.35 of the 128.4 mutations of a human zygote should
be detrimental, according to our specific definition of
this term.
Discussion
The spectrum of mutations observed in hemophilia B
is not unlike that of sequence divergence between closely
related species. Point mutations dominate, followed by
small deletion/insertions and only a few gross deletions
or other gross rearrangements. The latter are probably
influenced by features of chromosome organization that
are as yet poorly delineated, such as the distribution of
replication start sites, the arrangement of chromosomes
on the nuclear matrix, and the presence, extent, orien-
tation, and identity of repeated sequences; it is therefore
difficult to obtain estimates of their occurrence that may
be truly representative of gross deletions, insertions, or
inversions in the whole genome. More-reliable estimates
are possible for point and small mutations. We have
determined the rates of transitions at CpG and non-CpG
sites, of transversions, and of small deletions/insertions
found in hemophilia B, and we have used both these
values and the ratio of male to female mutation rates to
obtain rates relevant to the whole genome.
To arrive at the type-specific mutation rates for he-
mophilia B, we had to define the relevant biological tar-
gets and the numbers of independent mutations in our
U.K. sample. Both tasks were performed by use of ec-
onomical and conservative assumptions. We defined the
target for hemophilia B mutations by using observa-
tional data, rather than theoretical inferences based on
conservation and presumed relevance of changes in the
factor IX sequence, and we considered as a single event
identical mutations that could not be positively shown
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Table 4
Comparison of Autosomal Type-Specific Mutation Rates Derived from U.K. Hemophilia B Population and
Interspecies Divergence of X and Y Chromosome Sequences
DATA
TYPE OF MUTATION
Transitions
Transversions
All Base
Substitutions
Small Deletions/
Insertions AllCpG Non-CpG
A 1.32 # 107 9.88 # 109 9.28 # 109 2.08 # 108 6.49 # 1010 2.14 # 108
B 6.32 # 109 4.81 # 1010 2.89 # 1010 8.51 # 1010 3.51 # 1011 8.87 # 1010
A/B 20.9 20.5 32.1 24.4 18.4 24.0
NOTE.—Row A: estimates of rates per base per generation, from hemophilia B, adjusted for autosomes, as
explained in text. Row B: estimates of rates per base per year, from divergence of X-chromosome sequences,
adjusted for autosomes, as explained in text. Row A/B: quotient of rates shown in rows A and B; this should
reflect length of current human generation, if the estimates in rows A and B are sufficiently coherent.
to be of independent origin. The latter may have resulted
in slight underestimation. Our values are higher than the
rates calculated by Ketterling et al. (1993) and by Som-
mer and Ketterling (1996). Those authors, however, re-
lied on data in the literature, rather than attempting to
estimate the overall mutation rate for hemophilia B; they
do not take into account the ratio of male to female
mutation rates when extrapolating from hemophilia B
to the whole genome, and their definition of the mu-
tational target for hemophilia B is less purely based on
observation in humans than is ours.
The base-substitution rate that we calculate from the
hemophilia B data is in reasonable agreement with ev-
olutionary rates for synonymous base substitution and
point mutations in pseudogenes (Li and Graur 1991;
Crow 1993). Similarly, the type-specific mutation rates
that we have obtained from our hemophilia B work are
in keeping with the rates derived from our study of the
divergence between X- and Y-chromosome sequences in
humans and chimpanzees (Anagnostopoulos et al. 1999;
present study). This would be expected if we have cor-
rectly defined the target of mutations able to cause he-
mophilia B and if this disease represents a good model
for the estimation of mutation rates in man. Interestingly,
we find clear evidence of overrepresentation of CpG sites
in the effective target for hemophilia B. This contributes
to the reported excess of CpG transition mutations in
hemophilia B (Koeberl et al. 1989; Green et al. 1992;
Giannelli et al. 1998). We have previously argued that
the tendency toward “CpG suppression” characteristic
of vertebrate DNA (Bird 1980) will be opposed by se-
lection with a strength directly proportional to the phe-
notypic effect of mutations affecting this dinucleotide.
This should result in preferential conservation of CpG
sites at essential positions within genes (Green et al.
1992). X-linked genes are maximally exposed to this
effect of natural selection, because of the monosomy for
the X chromosome in the heterogametic sex. Thus, a
relative enrichment for CpG sites in the critical target
of genes, especially X-linked genes, should have been
expected.
Our data on interspecies sequence divergence were not
from genes that are present on both the X and Y chro-
mosomes. Nevertheless, we have sought to ensure that
the sequences were representative both of the respective
chromosomes and of regions without unusual evolu-
tionary constraints. This was done by the sampling of
small DNA stretches at many haphazardly chosen lo-
cations in unique regions of the X and Y chromosomes.
Our data are in keeping with the concept of male-
driven evolution (Miyata et al. 1987; Shimmin et al.
1993; Ellegren and Fridolfsson 1997). The ratio of sex-
specific mutation rates calculated for hemophilia B, 8.64,
is greater than the ratio of 3.5 obtained for the period
of separate evolution of humans and chimpanzees, but,
of course, the average paternal age of modern man is
likely to be greater than that of his ancestors and the
chimpanzee. The ratio of sex-specific mutation rates in
hemophilia B is indeed fairly close to the ratio of germ-
line cell division in human males and females of parental
ages appropriate to our time (Drost and Lee 1995). This
underscores the role of cell replication in germline mu-
tagenesis but, of course, does not exclude the contri-
bution of other differences in the biology of the male
and female germlines to the definition of the sex-specific
mutation rates.
Our estimate of the spontaneous rate of detrimental
mutations in humans (1.35 per diploid) is in close agree-
ment with the recent estimate of detrimental mutation
rates in hominids, based on a comparison of synony-
mous and nonsynonymous rates in protein-coding
regions of different species, made by Eyre-Walker and
Keightley (1999). Those authors indirectly estimate the
number of all mutations that could negatively affect fit-
ness in evolving populations and suggest 4.2 amino
acid–altering mutations per diploid per generation. On
the basis of this estimate they suggest a rate of 1.6 del-
eterious mutations per diploid genome. They consider
this as a minimal value, because mutations in noncoding
regions are not accounted for, and they also take a con-
servative estimate of the number of genes in the human
genome—namely, 60,000.
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Our estimate is based on different premises, since we
do not consider the number of genes in the genome and
the level of conservation of several proteins in different
species but instead argue from a direct estimate of the
hemophilia B mutation rates, the effective target for such
a phenotypically detectable trait relative to the full size
of the factor IX gene, and the known size of the human
genome. We take into account mutations in noncoding
regions and all deletion/insertion changes and therefore
do not feel that ours is an underestimate on this account.
One could even argue that our estimate is likely to be
a maximum estimate, because the factor IX gene has no
functional homologues and therefore there is no redun-
dancy of its function in the human genome. This prob-
ably does not apply to all human genes. A great variety
of missense mutations cause hemophilia B, whereas mu-
tations in many other human genes lead to abnormal
phenotypes only when they are more disruptive; for ex-
ample, mutations of the dystrophin (Roberts et al. 1994)
or the adenomatous polyposis coli gene (Nagase and
Nakamura 1993) mostly result in recognizable pheno-
types when they cause premature termination of trans-
lation. The human genome is known to contain large
regions of very low gene density (e.g., the centromeric
region) where base substitutions may more frequently
be neutral. However, sometimes structural features of
some regions of the genome may result in unexpected
incidence of gross rearrangements, as found, for ex-
ample, in hemophilia A (Naylor et al. 1995), but such
predisposing structures are expected to be rare. On the
whole, our data suggest that a rate of detrimental mu-
tations per human zygote of ∼1 is highly plausible. Of
course, the greater the rate of detrimental mutations, the
greater is the problem of accounting for the survival of
the species. Sexual reproduction and recombination pro-
vide much-needed flexibility in the face of selection, and
Crow (1999), considering rates of detrimental mutations
to be k1, suggests that elimination of mutations in
bunches has probably had a role in the maintenance of
our species.
In conclusion, the study of hemophilia B mutations
in the population of the United Kingdom has allowed
the determination of “type-specific mutation rates” in
the X chromosome and autosomes. These rates are in
keeping with those which we obtain from consideration
of sequence divergences in the X and Y chromosomes
of humans and chimpanzees. The data from hemophilia
B and those from sequence divergence are both in keep-
ing with the concept of male-driven evolution. We also
show that the target for hemophilia B mutations is rich
in CpG nucleotides and suggest that this is because of
selection acting against the tendency of CpG suppression
that is characteristic of vertebrate DNA.
Finally, by considering the size of the target for he-
mophilia B mutations, relative to the whole factor IX
gene, we provide a definition-based estimate of the rate
of detrimental mutations per human zygote, operation-
ally different from that generally used in investigations
of genetic load, since it relies on extrapolation from a
specific clinically detectable phenotype.
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